Until recently, peptides were a conversation happening in two places: research labs and bodybuilding forums. Neither audience had much reason to talk to the other.
That changed fast.
GLP-1 drugs like semaglutide and tirzepatide went from clinical development to mainstream conversation with unusual speed. Suddenly, "peptide" was no longer a niche term. And once the category broke into public view, everything else came with it: recovery compounds, longevity compounds, cosmetic compounds, cognitive compounds — a growing list of molecules the internet now treats as if they hold the answer to nearly everything.
Some of this is real. Some of it is extrapolation dressed up as certainty.
The problem is not that peptides are fake. Several clearly matter, and the GLP-1 class already has some of the strongest clinical data of any major drug category this decade. The problem is that the market routinely collapses important distinctions — between animal data and human outcomes, between experimental compounds and approved medicines, between mechanistic promise and proven results.
Those distinctions are the whole game. This guide exists to help you see them clearly.
What peptides are, in plain English
A peptide is a short chain of amino acids. Proteins are long chains; peptides are short ones. Your body already makes thousands of them — insulin, oxytocin, and glucagon are all peptides you've heard of.
When people say "peptides" in the 2026 internet sense, they usually mean synthetic peptides being used as drugs, supplements, or research compounds. Some are FDA-approved medications. Some are available only through compounding pharmacies. Some are sold as "research chemicals" with no clinical approval at all.
That spread — from approved medicine to gray-market research compound — is the first thing to understand. The word "peptide" tells you almost nothing about what you're actually buying.
Why everyone is talking about peptides now
Three things converged.
The GLP-1 explosion. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produced the first weight-loss results in decades that actually matched the hype. Real clinical data, real outcomes, real demand. The category went from diabetes drug to cultural phenomenon in about 18 months.
Performance and longevity crossover. Compounds like BPC-157, TB-500, and CJC-1295 had been circulating in bodybuilding communities for years. As the GLP-1 conversation mainstreamed "peptide" as a word, the longevity/biohacker audience inherited an entire lexicon of compounds that had never been properly evaluated outside research settings.
Gray-market accessibility. "Research chemical" vendors, compounding pharmacies, and telehealth clinics created multiple parallel access paths. Depending on who you ask and where you look, the same molecule can be an approved medication, a compounded prescription, a research reagent, or a product you can't legally buy at all.
The result is a market where demand exploded faster than trustworthy information.
The six major peptide categories
Most peptides you'll read about fall into one of these buckets.
GLP-1 and weight loss. Semaglutide, tirzepatide, retatrutide. Strongest human evidence in the category. Approved medications. Access is the variable, not efficacy.
Recovery and healing. BPC-157, TB-500 (thymosin beta-4). Huge popularity, almost entirely animal or case-report evidence. Mechanistic stories get extrapolated aggressively.
Growth hormone secretagogues. CJC-1295, ipamorelin, sermorelin. Push the body to release more of its own growth hormone. Real endocrine effects, debated clinical relevance at typical doses, major safety considerations.
Longevity and cellular. MOTS-c, epitalon, humanin. Very thin human evidence. Interesting biology, limited clinical translation.
Sexual health. PT-141 (bremelanotide). FDA-approved for HSDD. Also used off-label.
Cognitive. Semax, selank. Russian-origin compounds. Some human data, limited translation to Western clinical frameworks.
The evidence problem
This is the issue that breaks most peptide conversations.
A compound can have:
- Strong mechanistic data (we know how it works in cells)
- Robust animal data (it did X in rats)
- Thin human data (a few small trials or case reports)
- And still zero real clinical guidance
When people talk about peptides online, they routinely use the first three to argue as if the fourth exists. That's how you get confident claims about compounds that have never been properly studied in humans.
The Peptide Addict uses a simple rule: human outcomes outrank mechanisms, animal studies, anecdotes, and marketing. Every time. If we can't find human evidence, we say so directly.
The legality and access reality
This is where most coverage gets foggy on purpose.
Peptides in the US exist on a spectrum:
- FDA-approved and prescribed — semaglutide (Ozempic), tirzepatide (Mounjaro), PT-141 (Vyleesi). Straightforward prescription medications.
- Compounded — made by licensed compounding pharmacies under specific conditions. This category has shifted significantly as shortages resolved and FDA guidance changed.
- Research use only — sold by "research chemical" vendors with disclaimers. Not legal to administer to humans, but widely purchased for that purpose.
- Unapproved and gray — compounds that don't fit any clean category.
We cover the legal landscape in a dedicated guide. The short version: if you don't know which category a compound falls into, you don't know what you're actually buying.
The vendor problem
Most "peptide review" sites have a commercial relationship with the vendors they rank. That's not automatically disqualifying, but it means you need to know how to read the rankings.
The common tells:
- Affiliate disclosures buried or missing
- Reviews that read like product copy
- Scoring systems that always conveniently favor the top affiliate partners
- "Independent" sites owned by the same operators as the vendors they review
The Peptide Addict publishes its vendor review methodology and its affiliate disclosure on dedicated pages. Our editorial ratings cannot be altered by commercial relationships. That rule is the whole point of the site.
The Peptide Addict framework
When we cover a peptide, we separate four things that usually get collapsed into one:
- Evidence. What human data actually exists? How strong is it? What's still animal-only?
- Safety. What are the known risks? What's unknown?
- Legal and access reality. Approved, compounded, research-use, or gray?
- Market integrity. Who profits from the story? Where are incentives distorting the narrative?
Every major article carries a visible scorecard across six dimensions, including a metric we call hype gap — how far public enthusiasm exceeds the quality of evidence. A compound can be wildly popular and still have a huge hype gap. That combination shows up a lot in this category.
How to think about peptides as a category
Three mental buckets will get you most of the way:
What is actually promising. A small number of compounds have real human data, real clinical outcomes, and real safety information. GLP-1 agonists for weight loss and diabetes are the clearest example. These deserve to be taken seriously on their evidence.
What is overhyped. Compounds with interesting mechanisms and strong anecdotal followings but thin human data. Popular doesn't mean proven. Most of the recovery-peptide category lives here.
What is unknown. Compounds where the evidence is so limited that confident claims in any direction are unjustified. This isn't a criticism — it's a factual description of where the research is.
If you're reading something that refuses to make these distinctions, you're probably reading marketing.
Common mistakes beginners make
Treating mechanism as proof. "It activates X pathway" is an interesting starting point, not evidence of real-world benefit.
Trusting popularity as a signal. Just because a compound is everywhere on Reddit doesn't mean it works. It means it's everywhere on Reddit.
Ignoring the legal layer. The legal status affects everything — vendor quality, price, accountability, and what you're actually getting in the vial.
Reading "peptide review" sites without checking incentives. If a site ranks vendors, find the affiliate disclosure before you trust the ranking.
Overweighting animal studies. A mouse is not a person. Wound healing in a rat tendon is not wound healing in a human tendon.
Underweighting side effects. If a compound has real effects, it has real side effects. Anyone telling you otherwise is selling you something.
Where to go next
Start with the foundational pages, then explore specific compounds.
- Are Peptides Legal in 2026? — the legal and access reality, explained.
- How to Evaluate a Peptide Vendor — the 12 questions that matter more than coupon codes.
- BPC-157: What Human Evidence Actually Exists? — a case study in popularity outrunning the evidence base.
- Semaglutide vs Tirzepatide vs Retatrutide — the GLP-1 class, compared.
Finally, someone explained this clearly without trying to sell you something. That's the bar we're trying to hit. If we succeed, come back — the library grows every week.